Corporate News

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

2020

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.